Welcome to our dedicated page for IM Cannabis Common Shares news (Ticker: $IMCC), a resource for investors and traders seeking the latest updates and insights on IM Cannabis Common Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IM Cannabis Common Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IM Cannabis Common Shares's position in the market.
IM Cannabis Corp. reported its financial results for Q1 2024, showing a 13% revenue increase compared to Q4 2023. Gross profit increased by 125% but dropped by 39% compared to Q1 2023. Operating expenses decreased by 29%, with a 12% increase in Non-IFRS Adjusted EBITDA loss. The Company plans a private placement of secured convertible debentures. Despite revenue effects from the Israel-Hamas war, IMC expects growth in the German market post-legalization.
IM Cannabis Corp. will report its operational and financial results for the first quarter of 2024 on May 8th, 2024. The company, a key player in the medical cannabis sector operating in Israel and Germany, will hold a zoom conference at 9:00am ET to discuss the results with investors. A recording will be available on the company's website within 24 hours.